





ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ijmf20

Guidelines on prevention of preterm birth

Shama Munim, Zaheena Islam, Nishat Zohra, Haleema Yasmin & Razia Korejo

To cite this article: Shama Munim, Zaheena Islam, Nishat Zohra, Haleema Yasmin & Razia Korejo (2022): Guidelines on prevention of preterm birth, The Journal of Maternal-Fetal & Neonatal Medicine, DOI: 10.1080/14767058.2022.2045582

To link to this article: https://doi.org/10.1080/14767058.2022.2045582

	Published online: 03 Mar 2022.
	Submit your article to this journal 🗷
a Q	View related articles ☑
CrossMark	View Crossmark data 🗹

Taylor & Francis Taylor & Francis Group

GUIDELINES



Guidelines on prevention of preterm birth

Shama Munim^a, Zaheena Islam^b, Nishat Zohra^c, Haleema Yasmin^d and Razia Korejo^e

^aDepartment of Obstetrics and Gynecology & Fetal Medicine, Jinnah Medical and Dental University, Karachi, Pakistan; ^bDepartment of Obstetrics and Gynecology, Aga Khan University Hospital, Karachi, Pakistan; ^cDepartment of Obstetrics and Gynecology, Isra University Hyderabad, Hyderabad, Sindh, Pakistan; ^dDepartment of Obstetrics and Gynecology, Jinnah Postgraduate Medical Center, Karachi, Pakistan; ^eDepartment of Obstetrics and Gynecology, Baharia University, Karachi, Pakistan

ABSTRACT

This guideline has been prepared by the National Maternal Fetal Medicine guidelines committee and approved by the Society of Obstetricians and Gynecologists Pakistan. These recommendations will enable the practicing clinicians to optimally manage pregnancies at risk of preterm birth.

ARTICLE HISTORY

Received 23 January 2022 Accepted 20 February 2022

KEYWORDS

Risk factors; preterm birth; screening; prevention

1. Introduction

Preterm birth (PTB) refers to delivery that occurs before 37 weeks of gestation [1,2]. It is the single most important determinant of adverse Perinatal and infant outcomes, in terms of survival and quality of life [2]. A vast majority of these children die due to complications of preterm birth [3,4]. and many survivors have lifetime disability. Pakistan is among the 15 countries with a high Perinatal mortality [4]. Therefore Screening for this condition is a priority.

In 70–80% of PTBs are spontaneous and nearly half are born to women with no previous history or are nulliparous [3]. Women with a previous history of Preterm delivery has a 14–15% risk of having a delivery before 35 weeks of gestation compared to 3% if the previous delivery was at term [5,6].

Strategies for prediction of Preterm birth include demographic features and risk factors, sonographic and biochemical markers [1,6]. Following screening, interventions progesterone or cerclage can be offered to women who are classed as high-risk [7].

2. Risk factors

Risk factors that are studied include demographic factors, infections and uterine factors. There is no convincing evidence to support its use routinely [8]. However, common risk factors one can look for at the time of first antenatal visit are given in Table 1.

2.1. Risk reduction

2.1.1. Initial assessment

- Assessment of risk preconception [12].
- Identify risk factors at the time of first antenatal visit.
- Life style modification including cessation of smoking.
- Optimization and control of preexisting medical conditions including hypertension and Diabetes and metabolic syndrome.
- Counseling regarding the risk of PTB in women with twin pregnancy and IVF.

2.1.2. Screening for infection

- Screening for asymptomatic bacteriuria.
- Bacterial vaginosis.

3. Prediction of PTB by cervical length (CL)

Transvaginal ultrasound for cervical length measurement is the gold standard for prediction of Spontaneous Preterm birth. The risk is inversely related to the cervical length [13–15]. Level of Evidence Grade 11B

When performed by appropriately trained individuals, it is found to be sensitive and highly reproducible [13,14]. Level of evidence Grade 11B. Transvaginal scan for cervical length measurements are unaffected

Table 1. Risk factors.

Maternal	Obstetric risks	Uterine factors
Age <18 or above 40 years [9].	Previous or family history of Preterm [11]	Uterine malformations [6] Conization of cervix.
High or Low BMI [10] PCOS	Previous history of second trimester abortion	Polyhydramnios
Nulliparous	Lack of antenatal care	Multiple pregnancy [9]
Smoking/Substance abuse [10]	Lack of continuity of care	Infections UTI, bacterial vaginosis [6]
Low socioeconomic status [10]	Vaginal bleeding [6]	IVF pregnancy [6]

by maternal obesity, cervical position, and shadowing from fetal parts [13].

3.1. Who should be screened?

- Those with prior history of spontaneous Preterm birth/PPROM [Grade1A]
- Previous history of second trimester miscarriage [13].
- History of uterine anomalies and previous history of surgery of the cervix.
- Cervical length screening can be considered in women from low-risk group. [Grade IIB]. It can only be implemented with adherence to strict guidelines [13] Level of evidence Grade 11A.

3.2. Conditions where cervical screening is not indicated: level of evidence grade 11B

- Those with ruptured membranes [13].
- With cerclage in place.

3.3. When to perform cervical assessment during pregnancy?


- In low-risk women it is recommended that the examination is performed at the time of anomaly scan.
- In high-risk women there is no consensus on the timing and frequency of cervical assessment [13]. However, cervical length can be performed done at 12–13 weeks and 6 days of pregnancy along with the Nuchal Translucency screening scan and after excluding major anomalies. Level of Evidence 1A.

3.4. Criteria for acceptable cervical length measurement

- Bladder should be empty [7].
- Prepare the clean probe by applying a cover.
- Guide the probe to the anterior fornix after introducing it gently.

- Obtain the sagittal long axis view of the entire cervix
- The image of the cervix fills 67–75% of the screen.
- Landmarks to be noted are:
 - ^ Both Internal and external are seen clearly.
 - ^ Cervical length is visible throughout the length.
 - ^ Funneling and debris need to be noted and documented.
- Calipers are placed clearly.
- Examination is performed over a period of time.
- Shortest cervical length is noted of the three good images.
- Fundal and suprapubic pressure is avoided.

Measurement of the Cervix



Adapted from Berghella V, Ultrasound Obstet Gynecol 1997:10;161 [16].

3.5. Frequency of screening in the highrisk women

- Serial cervical assessment is performed every one to two weeks and suture is applied only if cervical length becomes equal to or less than 25 mm [13]. Level of evidence Grade 1.
- Funneling with cervix <25 mm has shown a good predictive value for preterm birth in high-risk women [17]. However, addition of funneling to the cervical length >25 mm does not increase the prediction of PTB [17].



3.6. What is the cut off for offering intervention?

- The risk of spontaneous preterm birth is related to the cervical length and depends on a priori risk. A cervical length of <25 mm between 16 and 24 weeks is considered to be short [7].
- Women with cervical length <25 mm tends to deliver significantly earlier compared to those with measurement more than 25mm [8]. In high-risk women cervical length <25 mm between 14 and 18 weeks of gestation has a positive predictive value of 70% compared to 40% at 18-22 weeks of gestation [7].
- Therapeutic interventions can be offered if cervical length is <25mm.

4. Interventions

Vaginal progesterone and cerclage are the two interventions proven to be effective in reducing the risk of PTD. RCTs have shown that they reduce the risk of preterm delivery and improve perinatal outcome [18,19].

4.1. Progesterone

It is by far the most studied intervention for Preterm birth prevention [19,20]. RCTs have demonstrated significant reduction in PTB with the use of this intervention [19,20].

4.1.1. The use in those with previous history of PTD

Progesterone use in women with previous history resulted in reduced risk of Preterm delivery before 34 weeks of gestation (RR.31) [20]. The perinatal mortality is reduced by half. (RR0.45) [21] Use of vaginal micronized Progesterone reduces the risk of respiratory distress syndrome, neonatal morbidity and admission to NICU [7].

It is given both by intramuscular and Vaginal route [14,15]. In a meta-analysis by Jarde et al. the use of vaginal progesterone significantly reduced preterm birth <33 weeks (OR.29) [22].

4.1.2. Progesterone use with short cervix

A meta-analysis has shown that the use of vaginal micronized progesterone significantly reduces preterm birth <34 weeks of gestation in women with a short cervix. (OR 0.45) In a meta-analysis on individual patient data vaginal progesterone was found to significantly reduce the risk of PTB [18]. Both Neonatal morbidity and mortality are significantly reduced in women using progesterone [19].

4.1.3. Use of progesterone in twin pregnancy

Twin or higher order pregnancy with a short cervix will benefit from the use of progesterone. However, its use is not seen to improve the risk of PTD in those with a normal cervix, but it improves the neonatal outcome [22,23].

4.1.4. Recommendations

- Vaginal micronized Progesterone is considered to be safe and effective [21,24].
- It can be used for the prevention of preterm birth in singleton pregnancy with a prior PTB or short cervix. Level of evidence 1A.
- Vaginal micronized progesterone is also recommended in twins with a short cervix. Level of evidence 1A.
- Therapy can be initiated from 16 weeks onwards or any time short cervix is detected. It needs to be continued till 36 weeks of pregnancy. Level of evidence 1A.
- The dose of vaginal progesterone recommended in singleton pregnancy is 200mg daily and those with multifetal gestation is 400mg. The dose is taken preferably in the evening.
- Vaginal Progesterone can be used along with cervical cerclage.

4.2. Cervical cerclage

Cerclage is associated with reduction in Preterm birth before 37 weeks in women with prior Preterm birth and short cervix in comparison with no treatment [25]. Wealth of evidence suggests that cerclage reduces the risk of birth before 34 weeks by about 25%. Level of Evidence of Grade II C.

There is no difference in the efficacy of the vaginal progesterone and cerclage in case of a short cervix with previous history of Preterm Birth [26].

If the cervical length is less than 15 mm, cerclage is associated with significant reduction in Preterm birth [27].

Ultrasound indicated cerclage is usually applied from 16 to 22 weeks of Pregnancy. Cerclage can be applied from 12-14 weeks also excluding major anomalies at the time of Nuchal Translucency scan. This is mainly applicable to those with previous history of extreme Premature deliveries, repeated second trimester losses [28] Level of Evidence Grade 1 A.

4.2.1. Recommendations

It is recommended that cerclage is offered to women with:

• If the cervical length in the index pregnancy is less than 25 mm with previous history of Preterm birth. Level of Evidence. 1A.

- In the absence of any history, cerclage for short cervix is not recommended as it carries morbidity.
 Level of Evidence.
- Cerclage based on previous history alone is not recommended as Cerclage carries morbidity. Level of Evidence 1A.
- In women with previous history of cerclage, cerclage should be offered after performing transvaginal cervical length measurement. Level of Evidence 1VA.
- There is limited data is available on the role of rescue cerclage.
- Current evidence does not support the use of Cervical Pessary does not support the use of cervical pessary for the prevention of Preterm birth. Its use was not found to improve perinatal outcomes in singleton and twin pregnancies with a short cervix. Level of Evidence 1A.

4.2.2. Cerclage in twins and higher order

- Routine use of cerclage for twins is not recommended. Level of Evidence 1VA.
- We recommend Cerclage only after demonstration of short cervix on ultrasound. Level of Evidence 1VA.

Acknowledgement

The authors would like to thank the members of the Core Group of the National Guidelines Committee of the Society of Obstetrics and Gynecology, Pakistan. Also, we want to extend our gratitude and Special thanks to Professor Gian Carlo Di Renzo for providing us with his feedback during the preparation of this guideline.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

The authors have not received any funding to support this work.

References

- [1] Blencowe H, Cousens S, OesterGaard MZ, et al. National, reginal, worldwide estimates of the preterm birth rates in the year 2010 with time trends since 1990 for selected countries. A systematic analysis and implications. Lancet. 2012;379(9832):162–172.
- [2] Lui L, Oza S, Hogan D, et al. Global, regional and national mortality under 5 years of age in 2000-15. An updated systematic analysis and implications for

- the systematic analysis and implications for the sustainable developmental goals. Lancet. 2016;388: 2162–2172.
- [3] WHO. Preterm birth; 2016 [Updated November 2016; cited 2017 Mar 24]. http://www.who.int/mediacenter/ factsheets/fs363/en/.
- [4] Lozano R, Wang H, Foreman KJ, et al. Progress towards millennium development goals 4 and 5 on maternal and child mortality: an updated systematic analysis. Lancet. 2011;378(9797):1139–1165.
- [5] lams JD, Goldenberg RL, Mercer BM, et.al. The preterm prediction study: Recurrence risk of spontaneous preterm birth. Am J Obstet Gynecol. 1998;178(5): 1035–1040.
- [6] Oskovi Kaplan ZA, Ozgu-Erdinc AS. Prediction of preterm birth: maternal characteristics, ultrasound markers, and biochemical markers: an updated overview. J Pregnancy. 2018;2018:8367571.
- [7] Mella MT, Berghella V. Prediction of preterm birth. Cervical sonography. Semin Perinatol. 2009;33(5): 317–324.]
- [8] Ultrasonographic cervical length assessment in predicting Preterm birth in singleton pregnancies. J Obstet Gynecol. 2011;33(5):486–499.
- [9] WHO. WHO report: born too soon? The global action report on Preterm birth; 2012. www//hhtp.who.int.
- [10] Australian Institute of Health and Welfare. Australia's mother and babies; 2017. https://aihw.gov.au.
- [11] Yang J, Baer Berghella V, Chambers C, et al. Recurrence of preterm birth and early term birth. Obstet Gynecol. 2016;128(2):364–372.
- [12] lams JD, Berghella V. Care for women with prior preterm birth. Am J Obstet Gynecol. 2010;203(2):89–100.
- [13] Mc Intosh J, Feltovich H, Berghella V, et al. The role of routine cervical length screening in selected high and low risk women for preterm birth prevention. Society of maternal fetal medicine (SMFM) #40. Am J Obstet Gynecol. 2016;215:B1–B6.
- [14] Owen J, Yost N, Berghella V, National Institute of Child Health and Human Development, Maternal-Fetal Medicine Units Network, et al. Mid-trimester endovaginal sonography in women at high risk for spontaneous preterm birth. JAMA. 2001;286(11):1340–1348.
- [15] Berghella V, Bega G, Tolosa JE, et al. Ultrasound assessment of the cervix. Clin Obstet Gynecol. 2003; 46(4):947–962.
- [16] Berghella V, Kuhlman K, Weiner S, et al. Cervical funneling: sonographic criteria predictive of preterm delivery. Ultrasound Obstet Gynecol. 1997;10(3): 161–166.
- [17] Berghella V, Roman A. Does funneling increase the incidence of preterm birth in women with normal cervical length? Am Journal Obstet Gynecol. 2005;193(6): s147.
- [18] Conde-Agudelo A, Romero R, Nicolaides K, et al. Vaginal progesterone vs cervical cerclage to the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth and singleton gestation: a systematic review and indirect comparison meta-analysis. Am J Obstet Gynecol. 2013;208(1):42.e1-18–42.e18.



- [19] Romero R, Conde-Agudelo A, Da Fonseca E, et al. Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix; a meta-analysis of individual patient data. Am J Obstet Gynecol. 2018;218(2): 161-180.
- [20] Romero R, Nicolaides KH, Conde-Augeldo A, et.al. Vaginal progesterone decreases preterm birth less than 34 weeks of women on with a singleton pregnancy, previous preterm birth and a short cervix; an updated meta-analysis including the OPTIMUM study. Ultrasound Obstet Gynecol. 2016;48(3):308-317.
- [21] Norman JE. Progesterone and preterm birth. Int J Gynaecol Obstet. 2020;150(1):24-30.
- [22] Jarde A, Lutsiv O, Beyene J, et al. Vaginal progesterone, oral progesterone, 17OHPC, cerclage and pessary for preventing preterm birth in at risk singleton pregnancies. An updated systematic review and network meta-analysis. BJOG. 2019;126(5):556-567.
- [23] Dodd JM, Grivell RM, OBrien CM, et.al. Prenatal administration of progesterone for preventing

- preterm birth in women with a multiple pregnancy. Cochrane Database Syst Rev. 2017;10(10):CD012024.
- [24] Jain V, McDonald SD, Mundle WR, et al. Guideline No. 398: progesterone for prevention of spontaneous preterm birth. J Obstet Gynaecol Can. 2020;42(6): 806-812.
- [25] Alfirivec Z, Stampalija T, Medley N. Cerclage for prevention of preterm birth in singleton pregnancy. Obstet and Gynecol. 2016;128(2):364-372.
- [26] Conde Agudelo A, Romero R, Da Fonseca E, et al. Vaginal progesterone is as effective as cerclage to prevent preterm birth in women with singleton gestation, previous spontaneous preterm birth and a short cervix: updated indirect comparison meta-analysis. Am J Obstet Gynecol. 2018;219(1):10-25.
- [27] Liu Y, Chen M, Cao T, et al. Cervical cerclage and twin pregnancy. An updated systematic review and metaanalysis. Eur J Obstet Gynecol Reprod Biol. 2021;260: 137-149.
- [28] Brown R, Gagnon R, Delisle M-F. No. 373-cervical insufficiency and cervical cerclage. J Obstet Gynaecol Can. 2019;41(2):233-247.